Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Oculis (OCS) reported notifications of transactions by persons discharging managerial responsibilities. These relate to vesting and settlement of RSUs previously granted to directors, annual equity incentive awards to directors, and a one-time equity grant to a new director upon his election to the board.

AI-generated analysis. Not financial advice.

Key Figures

Registered resale shares: 494,259 shares Currently exercisable warrant: 59,310 shares Potential cash proceeds: $6,877,246.59 +5 more

8 metrics

Registered resale shares 494,259 shares Form F-3 resale registration

Currently exercisable warrant 59,310 shares Portion of warrant currently exercisable

Potential cash proceeds $6,877,246.59 If warrant fully exercised for maximum shares

Financing shares 5,432,098 shares Equity financings announced October 31, 2025

Gross proceeds $110.0 million Equity financings announced October 31, 2025

Offering price $20.25 per share Underwritten and registered direct offerings

Shares outstanding pre-offer 52,374,811 shares As of September 30, 2025

Shares outstanding post-offer 57,806,909 shares Expected after offerings and direct sale

Market Reality Check

Price: $30.29 Vol: Volume 242,693 is below t...

low vol

$30.29 Last Close

Volume Volume 242,693 is below the 20-day average of 515,839, suggesting limited trading interest ahead of this routine governance update. low

Technical Price at 30.285 remains above the 200-day MA of 22.69, indicating a longer-term uptrend despite the recent -3.67% move.

Peers on Argus

OCS fell -3.67% while peers were mixed: ABUS rose 1.71%, EYPT, QURE, TSHA and UP...

OCS fell -3.67% while peers were mixed: ABUS rose 1.71%, EYPT, QURE, TSHA and UPB declined between -1.05% and -6.98%. With no peers in the momentum scanner and no related peer news, the move appears more stock-specific than sector-driven.

Historical Context

4 past events · Latest: May 11 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
May 11	Q1 earnings update	Positive	-6.9%	Reported Q1 results, strong cash runway, and late-stage pipeline timelines.
May 07	Regulatory SPA news	Positive	+5.1%	FDA Special Protocol Assessment for PIONEER-1 Phase 3 Privosegtor trial.
May 05	Clinical conference data	Positive	-1.8%	Presented DME AWARE Delphi findings and reiterated June 2026 DIAMOND data.
Apr 21	AGM invitation	Neutral	+0.0%	Published notice and logistics for the 2026 Annual General Meeting.

Pattern Detected

Recent news has triggered mixed reactions: some positive clinical and regulatory milestones saw selling pressure, while others aligned with moderate gains.

Recent Company History

Over the past month, Oculis reported Q1 2026 results with cash of $277.6 million and runway into 2H 2029, yet shares fell -6.86%. A Special Protocol Assessment for the Phase 3 PIONEER-1 trial in optic neuritis led to a 5.1% gain, while ARVO-related DME AWARE and DIAMOND updates saw a modest -1.8% move. The AGM invitation had little impact. Today’s RSU vesting and director equity awards fit into routine governance activity against this backdrop of clinically focused catalysts.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-11-10

An effective Form F-3 dated November 10, 2025 registers the resale of up to 494,259 ordinary shares issuable from a warrant. Oculis is not selling securities under this prospectus and receives no proceeds from resales, but could receive up to $6,877,246.59 in cash if the warrant is fully exercised at strike prices of $12.17 and $18.64 per share.

Market Pulse Summary

This announcement details routine corporate governance activity: vesting of previously granted RSUs,...

Analysis

This announcement details routine corporate governance activity: vesting of previously granted RSUs, annual equity incentive awards to directors, and a one-time grant to a new director. Against a backdrop of recent clinical and regulatory milestones and prior equity financings, it mainly clarifies how management and the board are compensated in equity. Investors may watch upcoming DIAMOND and PIONEER-1 milestones, cash runway disclosures, and any further capital-raising steps for more material signals.

Key Terms

rsus

1 terms

rsus financial

"the vesting and settlement of RSUs previously granted to directors of the Company"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. Not financial advice.

05/15/2026 - 04:05 PM

ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company, the annual equity incentive awards granted to directors of the Company, and the one-time equity incentive award granted to a new director upon his election to the board of directors of the Company.

Attachments

FAQ

What transactions did Oculis (OCS) report on May 15, 2026?

Oculis reported notifications of transactions involving directors’ restricted stock units and equity awards. According to Oculis, these cover RSU vesting and settlement, annual director equity incentives, and a one-time equity award for a newly elected board member.

Which Oculis (OCS) directors had RSU vesting transactions on May 13, 2026?

According to Oculis, RSU vesting notifications were filed for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani and Robert Warner. These transactions reflect the vesting and settlement of previously granted restricted stock units to these board members.

What equity incentive awards did Oculis (OCS) directors receive in 2026?

Oculis filed notifications for annual equity incentive awards granted to several directors in 2026. According to Oculis, these annual grants form part of the board’s compensation structure and are documented in individual manager transaction notifications for each named director.

Did Oculis (OCS) grant equity to a new director in 2026?

Yes. Oculis reported a one-time equity incentive award for new director G. Perry. According to Oculis, this award was granted upon his election to the board and is disclosed in a dedicated manager transaction notification.

Why does Oculis (OCS) publish notifications of managers’ transactions?

Oculis publishes managers’ transaction notifications to disclose equity dealings by directors and similar insiders. According to Oculis, the reported 2026 items include RSU vesting, annual equity awards and a new director grant, supporting transparency around board-related share incentives.